Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient.
Zhou, D., Duyvesteyn, H.M.E., Chen, C.P., Huang, C.G., Chen, T.H., Shih, S.R., Lin, Y.C., Cheng, C.Y., Cheng, S.H., Huang, Y.C., Lin, T.Y., Ma, C., Huo, J., Carrique, L., Malinauskas, T., Ruza, R.R., Shah, P.N.M., Tan, T.K., Rijal, P., Donat, R.F., Godwin, K., Buttigieg, K.R., Tree, J.A., Radecke, J., Paterson, N.G., Supasa, P., Mongkolsapaya, J., Screaton, G.R., Carroll, M.W., Gilbert-Jaramillo, J., Knight, M.L., James, W., Owens, R.J., Naismith, J.H., Townsend, A.R., Fry, E.E., Zhao, Y., Ren, J., Stuart, D.I., Huang, K.A.(2020) Nat Struct Mol Biol 27: 950-958
- PubMed: 32737466 
- DOI: 10.1038/s41594-020-0480-y
- Primary Citation of Related Structures:  
6ZCZ, 6ZDH, 6ZDG, 6ZER, 6ZFO - PubMed Abstract: 
The COVID-19 pandemic has had an unprecedented health and economic impact and there are currently no approved therapies. We have isolated an antibody, EY6A, from an individual convalescing from COVID-19 and have shown that it neutralizes SARS-CoV-2 and cross-reacts with SARS-CoV-1 ...